CD274 and ovarian carcinoma: In the IMAGYN050 trial, it was shown that almost 2/3 of newly diagnosed stage III or IV ovarian carcinomas had a moderate PD-L1 expression (assessed by SP142 clone on immune cells), which was associated with the worst prognosis, mainly on immune cells rather than tumor cells.